{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:32Z","timestamp":1793727812977,"version":"4.6.1"},"reference-count":151,"publisher":"Annual Reviews","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:p>Cardiorenal syndrome (CRS) represents a complex interplay of pathophysiological processes that create a self-perpetuating cycle of heart and kidney dysfunction. While it is clearly understood how hemodynamic changes connect pathogenesis in the two organs, other processes are also in play. Some are the structural changes involving both the cellular and extracellular compartments that precede functional alterations. Fibrosis, which is initiated by an inflammatory response triggering myofibroblast activation and excessive extracellular matrix production, is a common denominator of heart and kidney pathology in CRS. This review focuses on fibroblast activities as a crucial factor in disease onset and progression in CRS. We explore how fibrosis in one organ can trigger or worsen dysfunction in the other organ, and we describe the key pathological signaling pathways of cardiorenal fibrosis, the extracellular matrix\u2013derived biomarkers that can aid clinical management and drug development, and the therapeutic opportunities that can be beneficial in CRS by targeting fibroblast activities.<\/jats:p>","DOI":"10.1146\/annurev-physiol-043024-115512","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:01:00Z","timestamp":1762290060000},"page":"183-202","source":"Crossref","is-referenced-by-count":4,"title":["Scarred by Fibrosis: The Heart\u2013Kidney Disease Connection"],"prefix":"10.1146","volume":"88","author":[{"given":"Juliana H.","family":"Boukhaled","sequence":"first","affiliation":[{"name":"1RD N\u00e9phrologie, Montpellier, France; email: Boukhaled@rd-n.org"},{"name":"2Universit\u00e9 de Toulouse, Faculty of Science and Engineering, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Martin","sequence":"additional","affiliation":[{"name":"3Nordic Bioscience A\/S, Cardiovascular and Renal Research, Herlev, Denmark"},{"name":"4Institute of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gayrard","sequence":"additional","affiliation":[{"name":"1RD N\u00e9phrologie, Montpellier, France; email: Boukhaled@rd-n.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0ngel","family":"Argil\u00e9s","sequence":"additional","affiliation":[{"name":"1RD N\u00e9phrologie, Montpellier, France; email: Boukhaled@rd-n.org"},{"name":"5N\u00e9phrologie Dialyse Saint Guilhem (NDSG), S\u00e8te, France"},{"name":"6Department of Nephrology, University Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[{"name":"3Nordic Bioscience A\/S, Cardiovascular and Renal Research, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Genovese","sequence":"additional","affiliation":[{"name":"3Nordic Bioscience A\/S, Cardiovascular and Renal Research, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22","reference":[{"issue":"9","key":"B1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","year":"2018","journal-title":"Circulation"},{"issue":"16","key":"B2","first-page":"E840","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"B3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"B4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"B5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac fibrosis: the fibroblast awakens","volume":"118","year":"2016","journal-title":"Circ. Res."},{"issue":"5","key":"B6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/CIRCRESAHA.123.324001","article-title":"Cardiovascular consequences of uremic metabolites: an overview of the involved signaling pathways","volume":"134","year":"2024","journal-title":"Circ. Res."},{"issue":"10159","key":"B7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"B8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"17","key":"B9","first-page":"3272","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"10","key":"B10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.5603\/KP.2016.0141","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"74","year":"2016","journal-title":"Polish Heart J"},{"key":"B11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00042.2012","article-title":"Renal autoregulation in health and disease","volume":"95","year":"2015","journal-title":"Physiol. Rev."},{"issue":"2","key":"B12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pcad.2011.01.003","article-title":"The cardiorenal syndrome in heart failure","volume":"54","year":"2011","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"9","key":"B13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ejheart.2007.05.010","article-title":"Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction","volume":"9","year":"2007","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"B14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"B15","first-page":"30","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"B16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.101.10.1130","article-title":"Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts","volume":"101","year":"2000","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/ki.1997.480","article-title":"Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts","volume":"52","year":"1997","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/ndt\/gfh813","article-title":"Chronic kidney disease as cause of cardiovascular morbidity and mortality","volume":"20","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"issue":"13","key":"B20","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jacc.2007.08.072","article-title":"Cardiorenal interactions. insights from the ESCAPE Trial","volume":"51","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"B21","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"B22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"B23","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","year":"2022","journal-title":"Kidney Int. Suppl."},{"issue":"10075","key":"B25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"B26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00467-013-2494-8","article-title":"Remnant nephron physiology and the progression of chronic kidney disease","volume":"29","year":"2014","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"B27","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbadis.2019.01.027","article-title":"Wnt\/\u03b2-catenin regulates blood pressure and kidney injury in rats","volume":"1865","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"8","key":"B28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/ndt\/gfh872","article-title":"Role of atrophic changes in proximal tubular cells in the peritubular deposition of type IV collagen in a rat renal ablation model","volume":"20","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"B29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mam.2018.06.002","article-title":"Cellular and molecular mechanisms of kidney fibrosis","volume":"65","year":"2019","journal-title":"Mol. Aspects Med."},{"issue":"8","key":"B30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nm.3218","article-title":"Origin and function of myofibroblasts in kidney fibrosis","volume":"19","year":"2013","journal-title":"Nat. Med."},{"issue":"11","key":"B31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41419-018-1157-x","article-title":"Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury","volume":"9","year":"2018","journal-title":"Cell Death Dis"},{"issue":"Suppl. 68","key":"B32","first-page":"S78","article-title":"Left ventricular hypertrophy in renal failure","volume":"54","year":"1998","journal-title":"Kidney Int"},{"issue":"11","key":"B33","doi-asserted-by":"crossref","first-page":"e002213","DOI":"10.1161\/JAHA.115.002213","article-title":"Association of left ventricular hypertrophy with a faster rate of renal function decline in elderly patients with non-end-stage renal disease","volume":"4","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"B34","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"B35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"8","key":"B36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jacc.2010.10.024","article-title":"Diastolic tissue doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction","volume":"57","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"B37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41580-024-00716-0","article-title":"Fibroblast and myofibroblast activation in normal tissue repair and fibrosis","volume":"25","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1046\/j.1523-1755.1998.00076.x","article-title":"Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5\/6 nephrectomized rats","volume":"54","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"B39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2005070730","article-title":"Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia\/reperfusion in rats","volume":"18","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"B40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrneph.2014.246","article-title":"Diverse origins of the myofibroblast-implications for kidney fibrosis","volume":"11","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.yjmcc.2015.11.025","article-title":"Mechanical control of cardiac myofibroblasts","volume":"93","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"B42","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI74783","article-title":"Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis","volume":"124","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"2","key":"B43","doi-asserted-by":"crossref","first-page":"151288","DOI":"10.1016\/j.ejcb.2023.151288","article-title":"Mechanical stress regulates the mechanotransduction and metabolism of cardiac fibroblasts in fibrotic cardiac diseases","volume":"102","year":"2023","journal-title":"Eur. J. Cell Biol."},{"issue":"6","key":"B44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"B45","doi-asserted-by":"crossref","first-page":"H1871","DOI":"10.1152\/ajpheart.00387.2003","article-title":"Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts","volume":"285","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"B46","doi-asserted-by":"crossref","first-page":"eaao4881","DOI":"10.1126\/sciadv.aao4881","article-title":"Tensile forces drive a reversible fibroblast-to-myofibroblast transition during tissue growth in engineered clefts","volume":"4","year":"2018","journal-title":"Sci. Adv."},{"issue":"6","key":"B47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1083\/jcb.200704042","article-title":"Myofibroblast contraction activates latent TGF-\u03b21 from the extracellular matrix","volume":"179","year":"2007","journal-title":"J. Cell Biol."},{"issue":"17","key":"B48","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.jacc.2020.03.024","article-title":"Basic biology of extracellular matrix in the cardiovascular system, part 1\/4: JACC Focus Seminar","volume":"75","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"B49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/ndt\/gfv301","article-title":"Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy","volume":"31","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"B50","doi-asserted-by":"crossref","first-page":"17328","DOI":"10.1038\/s41598-017-17470-3","article-title":"Urinary endotrophin predicts disease progression in patients with chronic kidney disease","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"B51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-1536-7-4","article-title":"The extracellular matrix in the kidney: A source of novel non-invasive biomarkers of kidney fibrosis?","volume":"7","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"2","key":"B52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.1711620207","article-title":"Distribution of type I collagen in human kidney diseases in comparison with type III collagen","volume":"162","year":"1990","journal-title":"J. Pathol."},{"issue":"10","key":"B53","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.0000140973.60992.9A","article-title":"Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis","volume":"110","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"B54","article-title":"Endotrophin, a collagen VI formation-derived peptide, in heart failure","volume":"1","year":"2022","journal-title":"NEJM Evid"},{"issue":"9","key":"B55","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.amjcard.2015.02.015","article-title":"Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease","volume":"115","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"B56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1152\/ajpheart.00274.2020","article-title":"Pressure overload generates a cardiac-specific profile of inflammatory mediators","volume":"319","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"101082","DOI":"10.1016\/j.mam.2022.101082","article-title":"Renal insufficiency and chronic kidney disease\u2014promotor or consequence of pathological post-translational modifications","volume":"86","year":"2022","journal-title":"Mol. Aspects Med."},{"key":"B58","doi-asserted-by":"crossref","first-page":"101010","DOI":"10.1016\/j.mam.2021.101010","article-title":"Irreversible post-translational modifications\u2014emerging cardiovascular risk factors","volume":"86","year":"2022","journal-title":"Mol. Aspects Med."},{"issue":"8","key":"B59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41581-024-00837-x","article-title":"Post-translational modifications in kidney diseases and associated cardiovascular risk","volume":"20","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"issue":"8","key":"B60","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/labinvest.2012.68","article-title":"Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy","volume":"92","year":"2012","journal-title":"Lab. Investig."},{"issue":"12","key":"B61","doi-asserted-by":"crossref","first-page":"e0143390","DOI":"10.1371\/journal.pone.0143390","article-title":"Matrix metalloproteinase-2 knockout and heterozygote mice are protected from hydronephrosis and kidney fibrosis after unilateral ureteral obstruction","volume":"10","year":"2015","journal-title":"PLOS ONE"},{"issue":"3","key":"B62","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.2353\/ajpath.2010.090188","article-title":"Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells","volume":"176","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"3","key":"B63","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/endrev\/bnad036","article-title":"Endotrophin, a key marker and driver for fibroinflammatory disease","volume":"45","year":"2024","journal-title":"Endocr. Rev."},{"key":"B64","doi-asserted-by":"crossref","first-page":"101680","DOI":"10.1016\/j.molmet.2023.101680","article-title":"Endotrophin neutralization through targeted antibody treatment protects from renal fibrosis in a podocyte ablation model","volume":"69","year":"2023","journal-title":"Mol. Metab."},{"issue":"8","key":"B65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.104.516963","article-title":"Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart","volume":"112","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"B66","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/HYPERTENSIONAHA.117.09045","article-title":"Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin \u03b21 interaction","volume":"69","year":"2017","journal-title":"Hypertension"},{"issue":"2","key":"B67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.kint.2022.03.029","article-title":"Susceptibility to kidney fibrosis in mice is associated with early growth response-2 protein and tissue inhibitor of metalloproteinase-1 expression","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"4","key":"B68","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1681\/ASN.V124736","article-title":"TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy","volume":"12","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"B69","doi-asserted-by":"crossref","first-page":"797137","DOI":"10.3389\/fcvm.2022.797137","article-title":"ADAMTS8 promotes cardiac fibrosis partly through activating EGFR dependent pathway","volume":"9","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"B70","doi-asserted-by":"crossref","first-page":"5572088","DOI":"10.1155\/2021\/5572088","article-title":"The downregulation of ADAM17 exerts protective effects against cardiac fibrosis by regulating endoplasmic reticulum stress and mitophagy","volume":"2021","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"13","key":"B71","first-page":"e87023","article-title":"ADAM17 substrate release in proximal tubule drives kidney fibrosis","volume":"1","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"B72","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/HYPERTENSIONAHA.112.196113","article-title":"Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase","volume":"60","year":"2012","journal-title":"Hypertension"},{"issue":"3","key":"B73","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCHEARTFAILURE.113.000996","article-title":"Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure","volume":"7","year":"2014","journal-title":"Circ. Heart Fail."},{"issue":"14","key":"B74","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction contributions of collagen and titin","volume":"131","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"B75","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ki.2009.234","article-title":"Deletion of LOX-1 attenuates renal injury following angiotensin II infusion","volume":"76","year":"2009","journal-title":"Kidney Int"},{"issue":"8","key":"B76","doi-asserted-by":"crossref","first-page":"e22427","DOI":"10.1096\/fj.202200573R","article-title":"Lysyl oxidase promotes renal fibrosis via accelerating collagen cross-link driving by \u03b2-arrestin\/ERK\/STAT3 pathway","volume":"36","year":"2022","journal-title":"FASEB J"},{"issue":"1","key":"B77","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cvr\/cvv214","article-title":"Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction","volume":"109","year":"2016","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"B78","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41419-018-0573-2","article-title":"Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor","volume":"9","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"B79","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1038\/s41598-018-25674-4","article-title":"Isozyme-specific comprehensive characterization of transglutaminase-crosslinked substrates in kidney fibrosis","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"B80","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41419-023-05622-5","article-title":"Tissue transglutaminase exacerbates renal fibrosis via alternative activation of monocyte-derived macrophages","volume":"14","year":"2023","journal-title":"Cell Death Dis"},{"issue":"12","key":"B81","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.ajpath.2015.08.004","article-title":"Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system","volume":"185","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"10","key":"B82","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","article-title":"Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts","volume":"33","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"B83","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.kint.2018.11.021","article-title":"Wnt\/\u03b2-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome","volume":"95","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"B84","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2010101079","article-title":"Targeted inhibition of \u03b2-catenin\/CBP signaling ameliorates renal interstitial fibrosis","volume":"22","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"B85","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1681\/ASN.2008060566","article-title":"Wnt\/\u03b2-catenin signaling promotes renal interstitial fibrosis","volume":"20","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"B86","first-page":"62","article-title":"Interplay between the renin-angiotensin system, the canonical WNT\/\u03b2-catenin pathway and PPAR\u03b3 in hypertension","volume":"20","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"issue":"1","key":"B87","doi-asserted-by":"crossref","first-page":"14886","DOI":"10.1038\/s41598-021-94169-6","article-title":"Inhibition of the canonical Wnt signaling pathway by a \u03b2-catenin\/CBP inhibitor prevents heart failure by ameliorating cardiac hypertrophy and fibrosis","volume":"11","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"B88","first-page":"9","article-title":"The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition","volume":"13","year":"2007","journal-title":"J. Manag. Care Pharm."},{"issue":"1","key":"B89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1681\/ASN.2014010085","article-title":"Multiple genes of the renin-angiotensin system are novel targets of Wnt\/\u03b2-catenin signaling","volume":"26","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"B90","first-page":"e008385","article-title":"FGF-23 (fibroblast growth factor-23) and cardiorenal interactions","volume":"14","year":"2021","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"B91","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","year":"2011","journal-title":"Kidney Int"},{"issue":"1","key":"B92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12882-018-1094-z","article-title":"The role of klotho in chronic kidney disease","volume":"19","year":"2018","journal-title":"BMC Nephrol"},{"issue":"15","key":"B93","doi-asserted-by":"crossref","first-page":"e024952","DOI":"10.1161\/JAHA.121.024952","article-title":"Fibroblast growth factor 23 and risk of new onset heart failure with preserved or reduced ejection fraction: the PREVEND Study","volume":"11","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"B94","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","year":"2011","journal-title":"J. Clin. Investig."},{"key":"B95","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2017.10.010","article-title":"Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure","volume":"253","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"B96","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.18632\/aging.202448","article-title":"Excessive fibroblast growth factor 23 promotes renal fibrosis in mice","volume":"13","year":"2021","journal-title":"Aging"},{"issue":"1","key":"B97","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41467-022-28096-z","article-title":"A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-\u03b2 signaling","volume":"13","year":"2022","journal-title":"Nat. Commun."},{"key":"B98","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1152\/physrev.00008.2011","article-title":"Matricellular proteins in cardiac adaptation and disease","volume":"92","year":"2012","journal-title":"Physiol. Rev."},{"issue":"10","key":"B99","first-page":"1","article-title":"The thrombospondins","volume":"3","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B100","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1126\/scisignal.aar2566","article-title":"Thrombospondin-1 promotes matrix homeostasis by interacting with collagen and lysyl oxidase precursors and collagen cross-linking sites","volume":"11","year":"2018","journal-title":"Sci. Signal."},{"issue":"2","key":"B101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1523-1755.2004.00395.x","article-title":"Thrombospondin-1 is a major activator of TGF-\u03b2 in fibrotic renal disease in the rat in vivo","volume":"65","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"B102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacbts.2024.01.010","article-title":"Thrombospondin-1 drives cardiac remodeling in chronic kidney disease","volume":"9","year":"2024","journal-title":"JACC Basic Transl. Sci."},{"issue":"9","key":"B103","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41374-020-0434-3","article-title":"Blocking thrombospondin-1 signaling via CD47 mitigates renal interstitial fibrosis","volume":"100","year":"2020","journal-title":"Lab. Investig."},{"key":"B104","doi-asserted-by":"crossref","first-page":"16042","DOI":"10.1038\/s41598-017-16201-y","article-title":"Cartilage intermediate layer protein 1 (CILP1): a novel mediator of cardiac extracellular matrix remodelling","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"B105","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1038\/s41467-023-41642-7","article-title":"Proteomics of CKD progression in the chronic renal insufficiency cohort","volume":"14","year":"2023","journal-title":"Nat. Commun."},{"key":"B106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.yjmcc.2018.02.006","article-title":"Cartilage intermediate layer protein-1 alleviates pressure overload-induced cardiac fibrosis via interfering TGF-\u03b21 signaling","volume":"116","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"5","key":"B107","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacbts.2020.01.016","article-title":"Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure","volume":"5","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"issue":"2","key":"B108","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ijms19020379","article-title":"Galectin-3: one molecule for an alphabet of diseases, from A to Z","volume":"19","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B109","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"19","key":"B110","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"B111","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","year":"2013","journal-title":"Circ. Heart Fail."},{"issue":"9","key":"B112","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/cells12091218","article-title":"Galectin-3 is associated with cardiac fibrosis and an increased risk of sudden death","volume":"12","year":"2023","journal-title":"Cells"},{"key":"B113","doi-asserted-by":"crossref","first-page":"17007","DOI":"10.1038\/srep17007","article-title":"Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices","volume":"5","year":"2015","journal-title":"Sci. Rep."},{"key":"B114","doi-asserted-by":"crossref","first-page":"748225","DOI":"10.3389\/fmed.2021.748225","article-title":"Identification of galectin-3 as potential biomarkers for renal fibrosis by RNA-sequencing and clinicopathologic findings of kidney biopsy","volume":"8","year":"2021","journal-title":"Front. Med."},{"issue":"2","key":"B115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"5","key":"B116","doi-asserted-by":"crossref","first-page":"e000760","DOI":"10.1161\/JAHA.112.000760","article-title":"Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure","volume":"1","year":"2012","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"B117","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s40620-024-02047-x","article-title":"Biomarkers in cardiorenal syndrome, a potential use in precision medicine","volume":"37","year":"2024","journal-title":"J. Nephrol."},{"key":"B118","doi-asserted-by":"crossref","first-page":"868658","DOI":"10.3389\/fcvm.2022.868658","article-title":"Biomarkers in cardiorenal syndrome and potential insights into novel therapeutics","volume":"9","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"B119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ajkd.2015.12.033","article-title":"Clinical use of the urine biomarker [TIMP-2] \u00d7 [IGFBP7] for acute kidney injury risk assessment","volume":"68","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.matbio.2025.03.001","article-title":"Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities?","volume":"137","year":"2025","journal-title":"Matrix Biol"},{"issue":"8","key":"B121","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.echo.2012.04.025","article-title":"Increased procollagen type I C-terminal peptide levels indicate diastolic dysfunction in end-stage renal disease patients undergoing maintenance dialysis therapy","volume":"25","year":"2012","journal-title":"J. Am. Soc. Echocardiogr."},{"issue":"8","key":"B122","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.3390\/jcm12083003","article-title":"Connection between cardiac fibrosis biomarkers and echocardiography parameters in advanced chronic kidney disease patients","volume":"12","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"B123","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/biom13020389","article-title":"Predictive value of collagen biomarkers in advanced chronic kidney disease patients","volume":"13","year":"2023","journal-title":"Biomolecules"},{"issue":"6","key":"B124","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00392-021-01898-9","article-title":"Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial","volume":"111","year":"2022","journal-title":"Clin. Res. Cardiol."},{"issue":"3","key":"B125","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/ijms24032064","article-title":"Serum and urine biomarkers related to kidney fibrosis predict kidney outcome in Czech patients with IgA nephropathy","volume":"24","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"B126","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/ckj\/sfz174","article-title":"Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients","volume":"14","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B127","doi-asserted-by":"crossref","first-page":"1122972","DOI":"10.3389\/fimmu.2023.1122972","article-title":"Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA-associated vasculitis","volume":"14","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"B128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biom13050792","article-title":"Endotrophin levels are associated with allograft outcomes in kidney transplant recipients","volume":"13","year":"2023","journal-title":"Biomolecules"},{"issue":"9","key":"B129","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.34067\/KID.0001132021","article-title":"Collagen type III and VI remodeling biomarkers are associated with kidney fibrosis in lupus nephritis","volume":"2","year":"2021","journal-title":"Kidney360"},{"issue":"6","key":"B130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ndt\/gfab163","article-title":"Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis","volume":"37","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"B131","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2337\/dc17-2392","article-title":"Higher collagen VI formation is associated with all-cause mortality in patients with type 2 diabetes and microalbuminuria","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"B132","doi-asserted-by":"crossref","first-page":"110104","DOI":"10.1016\/j.isci.2024.110104","article-title":"Instrumental variable and colocalization analyses identify endotrophin and HTRA1 as potential therapeutic targets for coronary artery disease","volume":"27","year":"2024","journal-title":"iScience"},{"issue":"2","key":"B133","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41588-024-02052-7","article-title":"Integrative proteogenomic analysis identifies COL6A3-derived endotrophin as a mediator of the effect of obesity on coronary artery disease","volume":"57","year":"2025","journal-title":"Nat. Genet."},{"key":"B134","first-page":"28","article-title":"Thrombospondin-1 regulation of latent TGF-\u03b2 activation: a therapeutic target for fibrotic disease","volume":"68","year":"2018","journal-title":"Matrix Biol"},{"issue":"9","key":"B135","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"B136","doi-asserted-by":"crossref","first-page":"e048016","DOI":"10.1136\/bmjopen-2020-048016","article-title":"Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol","volume":"11","year":"2021","journal-title":"BMJ Open"},{"issue":"9","key":"B137","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/hr.2010.112","article-title":"Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction","volume":"33","year":"2010","journal-title":"Hypertens. Res."},{"key":"B138","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"9","key":"B139","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"B140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","year":"2013","journal-title":"Kidney Int"},{"issue":"7","key":"B141","doi-asserted-by":"crossref","first-page":"e22410","DOI":"10.1096\/fj.202200243R","article-title":"SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy","volume":"36","year":"2022","journal-title":"FASEB J"},{"key":"B142","doi-asserted-by":"crossref","first-page":"106659","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B143","doi-asserted-by":"crossref","first-page":"873108","DOI":"10.3389\/fphar.2022.873108","article-title":"Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-\u03b21\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure","volume":"13","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"B144","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1111\/dom.15761","article-title":"Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: a post hoc analysis","volume":"26","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"B145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.3101","article-title":"Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials","volume":"26","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"1\u20132","key":"B146","first-page":"74","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","year":"2023","journal-title":"Am. J. Nephrol."},{"issue":"11","key":"B147","doi-asserted-by":"crossref","first-page":"e32229","DOI":"10.1016\/j.heliyon.2024.e32229","article-title":"Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression","volume":"10","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"B148","doi-asserted-by":"crossref","first-page":"E529","DOI":"10.1152\/ajpendo.00245.2023","article-title":"Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats","volume":"325","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"19","key":"B149","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"B150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0006-291X(72)80203-1","article-title":"Biochemical and biophysical research communications on the inhibition of lysyl oxidase by 8-aminopropionitrile","volume":"46","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"B151","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis","volume":"23","year":"2019","journal-title":"J. Cell. Mol. Med."}],"container-title":["Annual Review of Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-physiol-043024-115512?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:43:22Z","timestamp":1770777802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-physiol-043024-115512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1146\/annurev-physiol-043024-115512","relation":{},"ISSN":["0066-4278","1545-1585"],"issn-type":[{"value":"0066-4278","type":"print"},{"value":"1545-1585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}